Prof. Allan Bradley
FRS, FMedSci

Allan, a professor in the Dept. of Medicine at Cambridge University and a world-renowned researcher and entrepreneur, is the Founder and CEO of T-Therapeutics.

He is known for his pioneering role in the development of ES cell technology as a graduate student at the University of Cambridge, acknowledged by the 2007 Nobel Prize awarded to his thesis advisor Martin Evans. His laboratory has published numerous highly cited primary research articles, he has mentored many leading academics and he is an elected fellow of both the Royal Society and Academy of Medical Sciences.

Serving as the second Director of the Sanger Institute after Sir John Sulston, he was responsible for transitioning a focused genome-sequencing facility into a highly productive academic institute while stimulating a culture that enabled translation, including two spinouts that emerged from his own laboratory at Sanger: Kymab and PetMedix.

Allan is also a serial entrepreneur. He has co-founded six companies, two in the US and four in the UK. These include two unicorns: Lexicon’s $1bn debut on the NASDAQ was achieved 5 years after it was founded while Kymab was sold to Sanofi for $1.45bn in 2021. PetMedix, the animal health company he co-founded in 2018, was recently acquired by the leading animal health company Zoetis.